Adiponectin expression in fibrotic interstitial lung diseases: a case-control study

<bold>Background:</bold> Fibrotic interstitial lung diseases (f-ILDs) include a wide range of pulmonary disorders associated with fibrotic changes in lung parenchyma. Adiponectin (ACPR30) is the most abundant adipokine modulating inflammatory, fibrotic and proliferative pathways. <bold>Methods:</bold> We present a case-control study conducted at Pneumologia Vanvitelli, Monaldi Hospital, Naples, Italy. ACPR30 serum concentration was measured by ELISA. <bold>Results:</bold> 64 patients with f-ILDs and 45 controls were enrolled. Study population characteristics are reported in Table 1. Serum ACPR30 levels were notably lower in patients with f-ILDs versus controls (Fig. 1a). No difference in adiponectin expression were observerd among different f-ILDs (Fig. 1b). In CTD-ILDs, ACPR30 was associated with FEV1%(p=.023), FVC%(p=.011),DLCO%(p=.033). The ROC curve documented a remarkable accuracy of ACPR30 in discriminating f-ILDs patients versus controls (Fig. 1c). <bold>Conclusions:</bold> These data suggest a potential role of adiponectin as biomarker in f-ILDs <bold>Table 1:</bold> Study population. Data are reported as median value or absolute number(%) <table-wrap><object-id>erj;64/suppl_68/PA4251/T1</object-id><object-id>T1</object-id><object-id>t1</object-id><table><colgroup><col></col><col></col><col></col><col></col></colgroup><tbody><tr><td></td><td><bold>f-ILD</bold></td><td><bold>Controls</bold></td><td><bold>p</bold></td></tr><tr><td><bold>Gender(M)</bold></td><td>32(50)</td><td>21(47)</td><td>0.84</td></tr><tr><td><bold>Age</bold></td><td>70</td><td>62</td><td>0.25</td></tr><tr><td><bold>Smoking</bold></td><td></td><td></td><td></td></tr><tr><td><italic>Current</italic></td><td>5(8)</td><td></td><td></td></tr><tr><td><italic>Former</italic></td><td>34(55)</td><td></td><td></td></tr><tr><td><italic>Never</italic></td><td>23(37)</td><td></td><td></td></tr><tr><td><bold>BMI</bold></td><td>26.6</td><td>25.2</td><td>0.15</td></tr><tr><td><bold>Waist Circ (cm)</bold></td><td>90</td><td>90</td><td>0.68</td></tr><tr><td><bold>ILD Group</bold></td><td></td><td></td><td></td></tr><tr><td><italic>IPF</italic></td><td>23(37)</td><td></td><td></td></tr><tr><td><italic>CTD-ILD</italic></td><td>32(51)</td><td></td><td></td></tr><tr><td><italic>Other f-ILD</italic></td><td>8(13)</td><td></td><td></td></tr><tr><td><bold>Antifibrotics</bold></td><td>27(42)</td><td></td><td></td></tr><tr><td><bold>FEV1%</bold></td><td>87.5</td><td></td><td></td></tr><tr><td><bold>FVC%</bold></td><td>81.3</td><td></td><td></td></tr><tr><td><bold>DLCO%</bold></td><td>55.4</td><td></td><td></td></tr><tr><td><bold>FVC/DLCO</bold></td><td>1.44</td><td></td><td></td></tr><tr><td><bold>GAP Index</bold></td><td>3</td><td></td><td></td></tr></tbody></table></table-wrap> <fig><object-id>erj;64/suppl_68/PA4251/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><label>Figure 1:</label><caption> ACPR30 expression in f-ILDs </caption><graphic></graphic></fig>